Prognostic Role of Monocytic Myeloid-Derived Suppressor Cells in Advanced Non-Small-Cell Lung Cancer: Relation to Different Hematologic Indices.
Journal
Journal of immunology research
ISSN: 2314-7156
Titre abrégé: J Immunol Res
Pays: Egypt
ID NLM: 101627166
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
06
2021
revised:
20
09
2021
accepted:
22
09
2021
entrez:
21
10
2021
pubmed:
22
10
2021
medline:
8
2
2022
Statut:
epublish
Résumé
We recruited 40 cases of advanced NSCLC, stages III and IV, aged > 18-<70 years old, and eligible to receive chemotherapy with or without radiotherapy, along with 20 healthy controls of comparable age and sex; after diagnosis and staging of patients, blood samples were collected for flow cytometric detection of Mo-MDSCs. Significant accumulation of Mo-MDSCs in patients compared to their controls ( Mo-MDSCs represent one of the key mechanisms in the immunosuppressive tumor microenvironment (TME) to play major roles not only in the carcinogenesis of lung cancer but also in disease progression and prognosis and, in addition, predict the efficacy of immune checkpoint inhibitors; our results provided some support to target Mo-MDSCs and needed to be augmented by further studies.
Identifiants
pubmed: 34671684
doi: 10.1155/2021/3241150
pmc: PMC8523286
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3241150Informations de copyright
Copyright © 2021 Asmaa M. Zahran et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Cancer Cell. 2008 Nov 4;14(5):408-19
pubmed: 18977329
J Immunol. 2008 Jul 1;181(1):346-53
pubmed: 18566400
Cancer Res. 2013 Jul 1;73(13):3877-87
pubmed: 23633486
J Cancer. 2018 Jun 14;9(14):2436-2442
pubmed: 30026840
Cancer Immunol Immunother. 2014 Oct;63(10):1023-36
pubmed: 24947180
Proteomics. 2016 Jul;16(13):1881-8
pubmed: 27193397
Eur J Immunol. 2010 Dec;40(12):3347-57
pubmed: 21110318
J Immunol. 2009 Apr 15;182(8):4499-506
pubmed: 19342621
Front Oncol. 2019 Apr 26;9:295
pubmed: 31080780
J Exp Med. 2015 Mar 9;212(3):351-67
pubmed: 25667306
Oncol Lett. 2016 Dec;12(6):4785-4794
pubmed: 28101225
Lung Cancer. 2014 Jan;83(1):97-101
pubmed: 24189108
Cancer Immunol Immunother. 2013 Sep;62(9):1439-51
pubmed: 23760662
Cancer Res. 2007 Oct 15;67(20):10019-26
pubmed: 17942936
J Immunol. 2018 Jan 15;200(2):422-431
pubmed: 29311384
Am J Respir Crit Care Med. 2018 Sep 15;198(6):777-787
pubmed: 29617574
Int J Mol Sci. 2018 Dec 09;19(12):
pubmed: 30544863
Microrna. 2019;8(3):206-215
pubmed: 30652656
Oncol Res Treat. 2019;42(10):523-531
pubmed: 31319409
Oncoimmunology. 2018 Jul 30;7(10):e1494113
pubmed: 30288362
J Immunol. 2005 Dec 15;175(12):8200-8
pubmed: 16339559
J Clin Oncol. 2007 Jun 20;25(18):2546-53
pubmed: 17577033
J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45
pubmed: 19572148
J Thorac Oncol. 2016 Aug;11(8):1263-1272
pubmed: 27178984
Cancer Immunol Immunother. 2021 Mar;70(3):733-742
pubmed: 32918587
J Immunol. 2009 Jul 15;183(2):937-44
pubmed: 19553533
Asian Pac J Cancer Prev. 2019 Jun 01;20(6):1927-1933
pubmed: 31244320
Cancer Res. 2016 Jun 1;76(11):3156-65
pubmed: 27197152
Fukushima J Med Sci. 2018 Aug 29;64(2):64-72
pubmed: 30012939
J Exp Clin Cancer Res. 2016 Sep 29;35(1):157
pubmed: 27686848
J Immunol Res. 2014;2014:659294
pubmed: 25436215
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Immunol Immunother. 2010 Oct;59(10):1593-600
pubmed: 20414655
Immunity. 2013 Sep 19;39(3):611-21
pubmed: 24012420